Second fertility preservation surgery for early relapse of seromucinous borderline ovarian tumors

case-report OA: gold CC-BY-NC-ND-4.0
AI-generated summary by gemini-2.5-flash-lite, 2026-07-14

This study reports on the early relapse of seromucinous borderline ovarian tumors in reproductive-age women, highlighting transvaginal ultrasound's role in detection and the success of second fertility-sparing surgery followed by successful fertility treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-07, 2026-07-14 · read from full text

This paper reports two cases of early relapse of seromucinous borderline ovarian tumors (SMBTs) occurring shortly after fertility-sparing laparoscopic unilateral cystectomy, with each patient subsequently undergoing a second fertility-sparing laparoscopic cystectomy for contralateral ovarian lesions. In both cases, intraoperative rupture of the initial tumor led to FIGO stage IC1, while relapse was detected using transvaginal ultrasound and CA125 trend (mild elevations), despite preoperative MRI with unclear solid nodules; pathology after both second surgeries confirmed SMBT and negative peritoneal cytology. A major limitation is that the evidence is limited to two individual case reports without a comparative design, so the generalizability to relapse management is uncertain, and the authors note latent contralateral disease cannot be excluded. Relevance to endometriosis: the introduction discusses that a substantial proportion of seromucinous borderline tumors are associated with endometriosis and that preoperative differentiation from endometriotic cysts is required, though the cases themselves are framed around SMBT relapse and fertility preservation rather than endometriosis pathology.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

•The initial diagnosis was endometriosis; however, the postoperative diagnosis was a seromucinous borderline ovarian tumor.•Women of reproductive age experienced an early relapse of seromucinous borderline ovarian tumor after surgery.•Transvaginal ultrasound was useful for early diagnosis of relapse.•A second fertility preservation surgery was performed, and fertility treatment without relapse was ongoing.
Full text 12,739 characters · extracted from pmc-nxml · 5 sections · click to expand

Case

A 33-year-old woman with no history of pregnancy presented to our hospital with menstrual pain. We found an 8.5-cm right ovarian cyst by transvaginal ultrasonography and MRI and suspected an endometriotic cyst ( Fig. 2 A-C). The CA125 level was mildly elevated at 47.8 U/μl. We performed a laparoscopic right ovarian cystectomy. The ovarian tumor ruptured during the surgery, and the postoperative pathological diagnosis was SMBT stage IC1. Only 11 months after surgery, we found a 2.3-cm tumor with a 0.9-cm solid nodule in the contralateral left ovary by transvaginal ultrasonography ( Fig. 2 D-F). The solid part was clear on transvaginal ultrasonography, although it was slightly contrasted by MRI. Eight months after the ovarian tumor relapsed, it gradually grew to 4 cm, so we suggested that a second surgery be performed. Generally, an adnexectomy is recommended, although we decided to perform a second fertility-sparing surgery because the patient strongly wanted to preserve her fertility. The ovarian tumor was resected without rupture using laparoscopic assistance. The peritoneal cytology was negative, and the pathological diagnosis was SMBT. Fig. 2 (A–C) Images taken before the initial treatment: MRI T1 (A) shows a slightly high intensity monolocular 8.5-cm right ovarian cyst, MRI T2 (B) shows high intensity, and the transvaginal ultrasound scan (C) shows no nodules in an ovarian cyst. (D–F) Images of relapse, MRI T1 (D) shows a low intensity 3-cm right ovarian simple cyst, MRI T2 (E) shows high intensity, and the transvaginal ultrasound scan (F) shows 5-mm nodules in an ovarian cyst. (A–C) Images taken before the initial treatment: MRI T1 (A) shows a slightly high intensity monolocular 8.5-cm right ovarian cyst, MRI T2 (B) shows high intensity, and the transvaginal ultrasound scan (C) shows no nodules in an ovarian cyst. (D–F) Images of relapse, MRI T1 (D) shows a low intensity 3-cm right ovarian simple cyst, MRI T2 (E) shows high intensity, and the transvaginal ultrasound scan (F) shows 5-mm nodules in an ovarian cyst. She is followed every 3 months with transvaginal ultrasound and blood sampling to measure CA125 levels. One year postoperatively, no relapse of SMBT had occurred, and she had been receiving general infertility treatment.

Conclusion

BOT after cystectomy is prone to relapse, and the time of relapse may be early. Cystectomy or adnexectomy should be considered carefully when performing fertility preservation, as it can occur in the opposite ovary both synchronously and asynchronously. If a patient opts for cystectomy, we should explain to her that the relapse rate is high, and more careful follow-up is needed. If there is a relapse in the remaining ovary, and the patient strongly desires a second fertility-preserving surgery, cystectomy may be acceptable after a thorough explanation of the risks. Financial Support No specific funding was received for this study.

Discussion

In these two cases, a preoperative diagnosis of endometrial cyst was suspected, and a laparoscopic unilateral cystectomy was performed. The postoperative pathological diagnosis was SMBT, and the FIGO progression stage was stage IC1 due to ovarian tumor rupture during the surgery. In the case of the postoperative diagnosis of BOT, additional treatment is generally considered for total hysterectomy, bilateral adnexectomy, and omentectomy ( Komiyama et al., 2016 ). According to the Japanese guidelines, if a patient wants to preserve fertility, re-operation should be performed through unilateral adnexectomy, omentectomy, and peritoneal biopsy, or through careful follow-up ( Komiyama et al., 2016 ). However, there have been no definite conclusions regarding re-operation in the case of fertility preservation ( du Bois et al., 2013 , Fauvet et al., 2004 ). Raffele et al. reported no difference in relapse rates between patients who have undergone re-operation and those who have not, in the absence of findings other than primary ovarian tumors ( Fauvet et al., 2004 ). Additionally, there are reports mentioning no difference in progression-free survival (PFS) or overall survival (OS) between laparotomy and laparoscopy, and no difference in PFS or OS prognosis between surgical upstaging due to intraoperative tumor rupture ( du Bois et al., 2013 , Fauvet et al., 2005 , Jung et al., 2018 ). The consensus is that early BOT and salvage surgery after a relapse have good prognoses. In our cases, the patients were diagnosed with SMBT postoperatively, and the attending physician and the patients had a thorough discussion. The patients were then carefully followed up without requiring additional surgery. A prospective study by Palomba et al. examined patients with bilateral BOT in a group of patients with unilateral adnexectomy and cystectomy or bilateral cystectomy ( Palomba et al., 2007 ). The relapse rate was almost the same in both groups at approximately 60%, and it was reported that the time to relapse was short at 16 months (4–24 months) in the bilateral cystectomy group. Other reports have also shown that the relapse rate is 23% for ovarian cystectomy and 7% for adnexectomy ( Suh-Burgmann, 2006 ). If only cystectomy is performed, and no adnexectomy is added, early relapse may occur and care should be taken. Palomba et al. reported a higher pregnancy rate and shorter time to pregnancy in patients who underwent cystectomy compared to those who underwent adnexectomy ( Palomba et al., 2007 ). However, the pregnancy rate reportedly did not differ between patients who underwent adnexectomy and cystectomy ( Delle Marchette et al., 2019 ). The relapse rate of BOT is reportedly higher in patients who underwent ovarian cystectomy than in those who underwent adnexectomy ( du Bois et al., 2013 , Palomba et al., 2007 , Suh-Burgmann, 2006 ), although better ovary preservation and higher pregnancy rates are noted in patients who underwent cystectomy ( Palomba et al., 2007 ). As mentioned above, in cases of cystectomy alone, relapse seems to occur with a high frequency within shorter time frames. Indeed, in our cases, the relapse occurred early at 2 or 11 months postoperatively, although the average time to relapse of BOT is reportedly 4.7 years ( Fauvet et al., 2005 , Suh-Burgmann, 2006 ). Preoperative imaging showed no mass on the contralateral ovary and no intraoperative macroscopic abnormality, but SMBT tends to occur bilaterally, and the possibility that the tumor was already latent in the contralateral ovary cannot be denied. Thus, early diagnosis of relapse is needed after fertility-sparing surgery. In our cases, transvaginal ultrasonography, which showed nodules on the cyst wall, made the diagnosis easier. MRI was performed simultaneously, although the solid nodule was unclear. The most common site of BOT relapse has been reported to be the ovary, and follow-up with transvaginal ultrasound after a fertility preservation surgery is useful. The solid nodules of SMBT were faintly enhanced on MRI, and it was difficult to distinguish when the tumor was small. Additionally, since it is difficult to use MRI frequently in terms of medical resources, regular transvaginal ultrasound examinations are convenient and useful. Adnexectomy is common for patients with BOT who desire fertility preservation. However, BOTs can affect both ovaries synchronously or asynchronously. Nevertheless, despite relapse, BOTs have a good prognosis if they are operable, and no difference in survival rate was found between patients who underwent adnexectomy and cystectomy ( Suh-Burgmann, 2006 ). BOTs may occur in both ovaries in synchronism or asynchronism; therefore, it is necessary to sufficiently explain the risk to patients and to carefully decide between cystectomy and adnexectomy when fertility preservation is considered. There are various opinions, but especially in young people, it may be necessary to select adnexectomy or cystectomy considering the possibility of a relapse in the future, the diameter of the remaining ovaries after surgery, and ovarian reserve. In the present cases, when the second surgery was planned, the patients had a strong desire for fertility preservation. Thus, cystectomy was performed again because the relapse tumors were on the contralateral ovary. After the second cystectomy, there have been no signs of relapse. Both patients are currently undergoing general infertility treatment while carefully following up.

Introduction

Seromucinous borderline tumors (SMBTs) are rare, accounting for 4.8% of borderline ovarian tumors (BOTs). In contrast, 23–70% of SMBTs are associated with endometriosis, and a preoperative diagnosis requires differentiation from endometriotic cysts and malignancies associated with endometriosis ( du Bois et al., 2013 , Karpathiou et al., 2017 , Kim et al., 2010 ). Since 30% of SMBTs are observed in bilateral ovaries and are predominant in women in their 30 s and 40 s, the choice of fertility-sparing surgery should also be considered ( Karpathiou et al., 2017 , Kim et al., 2010 ). Standard surgical procedures (bilateral adnexectomy, total hysterectomy, and omentectomy) are commonly applied to relapse cases after fertility-sparing surgery ( Komiyama et al., 2016 ). We report SMBTs in two cases of early relapse after the first fertility-sparing surgery, which required a second fertility-sparing surgery. The study was approved by the Musashino Red Cross Hospital Review Board and was conducted in accordance with the relevant guidelines and regulations of the Institutional Review Board. We obtained a signed informed consent from all patients.

Coi Statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-14T06:11:53.302379+00:00
pubmed
last seen: 2026-05-13T22:24:26.422845+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: CC-BY-NC-ND-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine